http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

硫酸吗啡控释片和普通片单词及多次给药的药代动力学

邓艳萍, 王凯, 刘立京, 刘静雯, 蔡志基, 楼雅卿   

  1. 北京医科大学中国药物依赖性研究所, 北京 100083
  • 收稿日期:1997-03-05 修回日期:1997-09-01 出版日期:1997-12-15 发布日期:1997-12-15

Pharmacokinetics of Controlled Release and Immediate Release Morphine Sulphate Tablets after a Single Dose and Multiple Doses in Chinese Volunteers

Yan-Ping Deng, Kai Wang, Li-Jing Liu, Jing-Wen Liu, Zhi-Ji Cai, Ya-Qing Lou   

  1. National Institute of Drug Dependence; Beijing Medical University; Beijing 100083
  • Received:1997-03-05 Revised:1997-09-01 Online:1997-12-15 Published:1997-12-15

摘要:

健康志愿者10名, 随机交叉口服硫酸吗啡控释片(CRMS) 30 mg (30 mg×1)和硫酸吗啡普通片(IRMS) 20 mg (10 mg×2), 分别于服药前后各时点取静脉血, 用GC2MS测定血浆中吗啡含量。以药代软件程序处理, 分别求得CRMS和IRMS的Cmax 为19.38±3.80和21.27±6.21 ng/ml; tmax为2.36±0.37 h和0.55±0.16 h; t1/2β为3.53±0.87 h和3.03±0.74 h, 曲线下面积AUC为145.15±17.65和93.08±16.65 ng·h/ml。癌症病人多次口服硫酸吗啡至稳态, CRMS和IRMS的峰浓度分别为27.43±0.33 ng/ml, 22.68±0.16 ng/ml; 谷浓度分别为19.45±1.44 ng/ml; 18.14±0.49 ng/ml。

关键词: 硫酸吗啡控释片, 硫酸吗啡普通片, 药代动力学, 单次给药, 多次给药, GC-MS

Abstract: The pharmacokinetics of morphine sulphate was studied in 10 Chinese healthy volunteers after a single oral dose. Blood samples were collected before and after administration of controlled release tablets (CRMS, 30 mg) and immediate release tablets (IRMS, 20 mg). The plasma concentration of morphine was determined by GC MS. The pharmacokinetic parameters of controlled release tablets and immediate release tablets were calculated: Cmax was 19.38±3.80 and 21.27±6.21 ng/ml, tmax was 2.36 ±0.37 h and 0.56±0.16 h, t1/2β was 3.53±0.87 and 3.03±0.74 h, AUC was 145.15±17.65 and 93.08±16.65 ng/ml, respectively. The steady state plasma concentration of morphine sulphate in cancer patients after multiple doses was achieved, Cmax of CRMS and IRMS was 27.43±0.33 ng/ml and 22.68±0.16 ng/ml, Cmin of CRMS and IRMS was 19.45±1.44 ng/ml and 18.14±0.49 ng/ml, respectively.

Key words: Controlled release morphine sulphate tablet, Immediate release morphine sulphate tablet, Pharmacokinetics, Single dose, Multiple doses, GC-MS

Supporting: